Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00731211. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab
Study identification
- NCT ID
- NCT00731211
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- Pazopanib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2008
- Primary completion
- Apr 30, 2011
- Completion
- Aug 31, 2012
- Last update posted
- May 19, 2015
2008 – 2012
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Oncology Associates | San Francisco | California | 94115 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Watson Clinic Center for Cancer Care and Research | Lakeland | Florida | 33805 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Gulfcoast Oncology Associates | St. Petersburg | Florida | 33705 | — |
| Medical Oncology Associates of Augusta | Augusta | Georgia | 30901 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Central Maine Medical Center | Lewiston | Maine | 04240 | — |
| Grand Rapids Clinical Oncology Program | Grand Rapids | Michigan | 49503 | — |
| St. Louis Cancer Care | Chesterfield | Missouri | 63017 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| South Carolina Oncology Associates, PA | Columbia | South Carolina | 29210 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00731211, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2015 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00731211 live on ClinicalTrials.gov.